Amifostine (WR-2721, ethyol(TM)) can protect human endothelial but not tumor cells from cisplatin-induced cytotoxicity: An in vitro study

Mauro Moroni, Camillo Porta, Nicoletta Finotti, Elena Borasio, Rosaria Greco, Laura Bertorelli, Mario Regazzi-Bonora, Fulvio Marzatico

Research output: Contribution to journalArticle

Abstract

Amifostine (WR-2721, Ethyol(TM)) is a chemo- and radioprotective agent which is increasingly used in clinical practice to minimize antitumor therapy-induced toxicities. The key of this property of amifostine is certainly its selective action in terms of differential protection of normal tissue and not of tumor cells. Using HUVEC cells and three different cancer cell lines (A549 non-small cell lung cancer, DND-1A melanoma and HeLa cervical carcinoma) we provide evidence that amifostine could protect normal, and not cancer cells, from cisplatin (CDDP)-induced cytotoxicity in vitro. Furthermore, low doses of amifostine, easily attainable in vivo, can protect 50% of normal cells in vitro from CDDP-induced cytotoxicity.

Original languageEnglish
Pages (from-to)729-732
Number of pages4
JournalOncology Reports
Volume4
Issue number4
Publication statusPublished - Jul 1997

Keywords

  • Amifostine
  • Cancer cell lines
  • Cytoprotection
  • Human umbilIcal vein endothelial cells
  • Selective action

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Amifostine (WR-2721, ethyol(TM)) can protect human endothelial but not tumor cells from cisplatin-induced cytotoxicity: An in vitro study'. Together they form a unique fingerprint.

  • Cite this

    Moroni, M., Porta, C., Finotti, N., Borasio, E., Greco, R., Bertorelli, L., Regazzi-Bonora, M., & Marzatico, F. (1997). Amifostine (WR-2721, ethyol(TM)) can protect human endothelial but not tumor cells from cisplatin-induced cytotoxicity: An in vitro study. Oncology Reports, 4(4), 729-732.